pancreatic cancer
-
New MD Anderson Research Uncovers Drug Combo That Could Eliminate Pancreatic Cancer Tumors
Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.
-
Report: Cancer deaths are down but pancreatic cancer is growing, racial disparities persist
Targeted drugs and immunotherapies are among the advances that contribute to declines in incidence and deaths from non-small cell lung cancer, according to the Annual Report to the Nation on the Status of Cancer. But the trends are on the rise for some other cancers and racial disparities persist, highlighting the need to better understand these differences.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Biopharma has a brand new target: Cancer-specific collagen
Researchers at the University of Texas MD Anderson Cancer Center published a new study revealing that cancer cells make their own unique form of collagen to help them grown and proliferate. This means drug developers may have a new, highly specific target for oncology therapeutics.
-
Merus eyes tumor-agnostic path for cancer drug addressing rare genetic target
Cancer drug developer Merus has encouraging early results indicating its drug can address several different types of tumors characterized by NRG1, a rare gene fusion. The company believes the data could support a regulatory filing for the bispecific antibody drug.
-
Startup banks on immune-system memory to tackle cancer
Loki Therapeutics is advancing research that leverages the immune system’s ability to recall childhood vaccinations and direct it against cancer. The company’s lead therapy candidate could enter phase 1 clinical trials this year.
-
INVEST Pitch Perfect winner spotlight: Amplified Sciences targets early pancreatic cancer detection
Amplified Sciences emerged as the winner of the diagnostics track for the MedCity INVEST conference’s Pitch Perfect contest with PanCystPro, the test it is developing to address the problems encountered when determining whether pancreatic cysts are cancerous.
-
Drug at center of $1.7B BMS, Five Prime partnership fails in Phase II pancreatic cancer study
BMS told Five Prime that it does not have current plans to further sponsor clinical development of the drug cabiralizumab after the failure of the combo trial, with BMS’ Opdivo and chemotherapy, but would support some investigator-sponsored trials.
-
AstraZeneca, Merck drug gets approval as pancreatic cancer maintenance
The FDA approved Lynparza for patients with pancreatic cancer after chemotherapy whose tumors harbor a certain genetic mutation.
-
Halozyme to restructure after failure of pivotal pancreatic cancer study
The biotech company will shut down its development program for PEGPH20 and instead focus on its drug delivery technology program while laying off 55 percent of its workforce.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Memorial Sloan Kettering and Philips want to upgrade precision oncology
As part of a new research collaboration, Memorial Sloan Kettering Cancer Center and Philips will be using DNA sequencing technologies to better understand pancreatic cancer.
-
It’s on: Cornerstone gets green light for two pivotal cancer trials
Following two small Phase 1 trials, Cornerstone Pharmaceuticals announced Thursday that it has secured FDA-backing for pivotal trials of its lead drug in AML and late-stage pancreatic cancer.
-
A pancreatic cancer community that crowdsources new treatments
The scientific advisory board’s role is to ensure the information shared on the website is scientifically based and that it offers a potential option beyond the existing standard of care treatments.
-
Former Biogen R&D head launches exosome-based biotech with $80M
Former Biogen R&D chief Doug Williams is launching a biotech startup called Codiak BioSciences with $80 million. It is developing exosomes as a new diagnostic and therapeutic tool, beginning with pancreatic cancer.
-
Jimmy Carter will receive radiation for cancer that has spread to his brain – but still stays positive
Former President Jimmy Carter has been informed that cancer has now spread to his brain.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
